Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
49.3 PLN | -1.00% | -6.81% | -14.26% |
Sales 2024 * | 152M 37.64M 3.01B | Sales 2025 * | 218M 53.92M 4.31B | Capitalization | 1.14B 283M 22.61B |
---|---|---|---|---|---|
Net income 2024 * | -161M -39.91M -3.19B | Net income 2025 * | -119M -29.5M -2.36B | EV / Sales 2024 * | 7.02 x |
Net cash position 2024 * | 73.62M 18.25M 1.46B | Net Debt 2025 * | 18.41M 4.56M 365M | EV / Sales 2025 * | 5.32 x |
P/E ratio 2024 * |
-12.3
x | P/E ratio 2025 * |
-11
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 64.75% |
Latest transcript on Ryvu Therapeutics S.A.
1 day | -1.00% | ||
1 week | -6.81% | ||
Current month | -10.69% | ||
1 month | -12.28% | ||
3 months | -10.69% | ||
6 months | -21.99% | ||
Current year | -14.26% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | - | 31/12/06 | |
Hendrik Nogai
CTO | Chief Tech/Sci/R&D Officer | - | 31/01/22 |
Chief Operating Officer | 38 | 31/12/12 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 72 | - | |
Scott Fields
BRD | Director/Board Member | 69 | 13/06/23 |
Thomas Turalski
BRD | Director/Board Member | - | - |
Date | Price | Change | Volume |
---|---|---|---|
26/04/24 | 49.3 | -1.00% | 4,319 |
25/04/24 | 49.8 | +0.10% | 3,262 |
24/04/24 | 49.75 | -2.07% | 4,107 |
23/04/24 | 50.8 | -0.39% | 5,472 |
22/04/24 | 51 | -3.59% | 7,527 |
Delayed Quote Warsaw S.E., April 26, 2024 at 04:55 pm
More quotesEPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-14.26% | 282M | |
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.74B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |
- Stock Market
- Equities
- RVU Stock